We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

876 hedge funds and large institutions have $40B invested in Teva Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 290 increasing their positions, 310 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 135 | Existing positions closed: 69

79% more call options, than puts

Call options by funds: $1.18B | Put options by funds: $662M

50% more funds holding in top 10

Funds holding in top 10: 58 → 87 (+29)

34% more capital invested

Capital invested by funds: $29.9B → $40B (+$10.1B)

6% more funds holding

Funds holding: 823 → 876 (+53)

4.84% more ownership

Funds ownership: 55.28% → 60.12% (+4.8%)

6% less repeat investments, than reductions

Existing positions increased: 290 | Existing positions reduced: 310

Holders
876
Holders Change
+53
Holders Change %
+6.44%
% of All Funds
22.98%
Holding in Top 10
87
Holding in Top 10 Change
+29
Holding in Top 10 Change %
+50%
% of All Funds
2.28%
New
135
Increased
290
Reduced
310
Closed
69
Calls
$1.18B
Puts
$662M
Net Calls
+$522M
Net Calls Change
+$500M

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$999M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$771M
3
Capital Research Global Investors
Capital Research Global Investors
California
+$474M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$372M
5
IC
Institutional Capital
Illinois
+$270M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$430M
2
MIP
Mondrian Investment Partners
United Kingdom
-$244M
3
Renaissance Technologies
Renaissance Technologies
New York
-$145M
4
NTC
North Tide Capital
Massachusetts
-$105M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$99.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
SLAM
701
Swiss Life Asset Management
$271K +$255K +4,134 New
RCIM
702
Russell Clark Investment Management
United Kingdom
$263K – – –
RBC
703
Ronald Blue & Co
Georgia
$262K -$601K -9,725 -71%
CIM
704
Calvert Investment Management
Maryland
$261K -$3.21K -52 -1%
BC
705
Bartlett & Co
Ohio
$260K -$4.33K -70 -2%
SWP
706
Stratos Wealth Partners
Ohio
$257K +$242K +3,908 New
BCM
707
BTC Capital Management
Iowa
$256K +$241K +3,894 New
NIM
708
Northeast Investment Management
Massachusetts
$253K – – –
NAM
709
NTV Asset Management
West Virginia
$248K – – –
ATC
710
Argent Trust Co
Tennessee
$248K +$234K +3,781 New
S
711
SignatureFD
Georgia
$240K +$25.6K +415 +13%
Koshinski Asset Management
712
Koshinski Asset Management
Illinois
$239K +$6.18K +100 +3%
VNA
713
VNBTrust National Association
Virginia
$237K – – –
VIA
714
Vident Investment Advisory
Georgia
$237K +$223K +3,613 New
EWM
715
Elite Wealth Management
Washington
$236K – – –
SCM
716
Stonebridge Capital Management
California
$236K – – –
SEC
717
Seven Eight Capital
New York
$236K +$222K +3,600 New
GCAC
718
Guardian Capital Advisors (Canada)
Ontario, Canada
$235K – – –
STMM
719
South Texas Money Management
Texas
$235K +$222K +3,587 New
RIA
720
Regal Investment Advisors
Michigan
$231K +$6.3K +102 +3%
FHA
721
First Horizon Advisors
Tennessee
$231K +$114K +1,850 +111%
VFA
722
Voya Financial Advisors
Connecticut
$227K +$212K +3,438 New
SGAM
723
Smith Group Asset Management
Texas
$226K – – –
SAS
724
Spectrum Advisory Services
Georgia
$226K +$213K +3,450 New
FCM
725
Forester Capital Management
Illinois
$225K – – –
27 28
29
30 31

TEVA Hedge Fund Activity: Q4 2015 in Review

876 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2015, worth a combined $40B — up 34% from $29.9B a quarter earlier.

Buyers outnumbered sellers: 135 funds opened new TEVA positions and 69 closed out — a net gain of 66 holders — while 290 added to existing stakes and 310 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $999M. The largest seller was Franklin Resources, cutting an estimated $430M.

  • 876 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2015, up from 823 in Q3 2015.
  • Funds reported $40B of Teva Pharmaceuticals stock for Q4 2015, up 34% quarter-over-quarter.
  • 135 funds opened new Teva Pharmaceuticals positions in Q4 2015 and 69 closed out, a net change of +66 holders.
  • The largest Teva Pharmaceuticals buyer in Q4 2015 was Viking Global Investors, an estimated $999M added.
  • The largest Teva Pharmaceuticals seller in Q4 2015 was Franklin Resources, an estimated $430M sold.

Based on aggregated 13F filings for Q4 2015.